Pharma Research said it appointed Sohn Ji-hoon as its new CEO to enhance its global business competitiveness. The company announced on the 21st that Sohn will officially assume his duties in March, leading the company as its sole CEO.
Sohn Ji-hoon, an experienced global business professional, holds a degree in economics from Korea University and an MBA from Boston University. He began his career at the headquarters of multinational pharmaceutical company Bristol-Myers Squibb (BMS) and has since accumulated over 35 years of extensive experience in the pharmaceutical and biotechnology industries.
His previous roles include Executive Director of Global Business at Dong-A Pharmaceutical, GM of Baxter Korea, CEO of Dongwha Pharmaceutical, CEO of Hugel, and most recently CEO of Genuone Science.
Notably, during his tenure as Hugel CEO, Sohn successfully secured approvals for botulinum toxin products in the U.S., Europe, and China, leading the company to consecutive record-high revenues.
“Sohn possesses extensive experience and strategic leadership in both Korean and international pharmaceutical and biotech sectors,” a Pharma Research official said. “He will establish a stable presence in key overseas markets such as the U.S. and Europe, laying the foundation for Pharma Research’s transformation into a global company.”
Meanwhile, Kang Ki-seok, who has led Pharma Research for the past two decades, will transition into a non-executive advisory role to support the company’s sustainable growth.
